HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

TAS-121

selective covalent inhibitor of the mutant EGFR

Also Known As:

(S)-N-(4-amino-5-(quinolin-3yl)-6,7,8,9-tetrahydropyrimido(5,4-b)-8-yl)-2-propenamide

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - TAS-121: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - TAS-121: 2

Experts

1.	Miyadera, Kazutaka: 2 articles (12/2019 - 01/2019)
2.	Murakami, Haruyasu: 2 articles (12/2019 - 01/2019)
3.	Nishio, Makoto: 2 articles (12/2019 - 01/2019)
4.	Ohe, Yuichiro: 2 articles (12/2019 - 01/2019)
5.	Baba, Tomohisa: 1 article (12/2019)
6.	Hayashi, Hidetoshi: 1 article (12/2019)
7.	Hida, Toyoaki: 1 article (12/2019)
8.	Hosomi, Yukio: 1 article (12/2019)
9.	Imamura, Fumio: 1 article (12/2019)
10.	Kasahara, Kazuo: 1 article (12/2019)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/01/2019 - "Purpose We investigated the safety, tolerability, pharmacokinetics, and efficacy of TAS-121, a novel, potent, and highly selective third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in Japanese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) previously treated with EGFR-TKI. " 12/01/2019 - "Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations."
2.	Neoplasms (Cancer) 01/01/2019 - "TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X."

Related Drugs and Biologics

1.	ErbB Receptors (EGF Receptor)
2.	Tyrosine Kinase Inhibitors